Efficacy and safety of recombinant human interleukin -2 in the adjuvant treatment of relapsing infiltrative pulmonary tuberculosis
نویسندگان
چکیده
Objective: To study the efficacy and safety of recombinant human interleukin-2 in the adjuvant treatment of relapsing infiltrative pulmonary tuberculosis. Methods: 198patients with reactivation tuberculosis were randomly divided into the test group and the control group. The dosing regimen was anti-tubercular agents and recombinant human interleukin-2 in the test group, and only the anti-tubercular agents in the control group. Conventional dose of anti-tubercular agents according to the clinical application of recombinant human interleukin-2 is 200 000 units. Results: The rate of sputum negative conversion and rate of focus absorption in the test group was higher than that in the control group (P<0.05). Although the rate of cavity closure in the test group is higher than the control group. Compared with the two groups the differences were not statistically significant (P>0.05). The ratio of CD4 and CD4/CD8 in the test group increased significantly at the third, and eighth months after the treatment, and it had the statistical significance compared with the control group (P<0.05).The level of soluble interleukin-2 receptors in the test group decreased significantly, and it had significantly differences compared with the control group (P<0.05).No serious adverse events were reported in the two groups. Conclusions: Recombinant human interleukin-2 is safe and effective as adjuvant treatment of relapsing infiltrative pulmonary tuberculosis. [Cui Deguang, Zhu Wenjuan. Efficacy and safety of recombinant human interleukin -2 in the adjuvant treatment of relapsing infiltrative pulmonary tuberculosis. Life Sci J 2014; 11(7):543-547] (ISSN: 1097-8135). http://www.lifesciencesite.com. 73
منابع مشابه
P120: Efficacy and Safety of Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disorder of central nervous system. This demyelinating disease affects more than 2.3 million people world wild. Most of patients are young adult. The most common type of MS is relapsing remitting multiple sclerosis (RRMS). However there is no cure, available modifying therapies has revolutionized the care of patients with RRMS. Interferon (IFN) be...
متن کاملEvaluation of immunogenicity and protective efficacy of recombinant ptfA of avian Pasteurella multocida
Avian Pasteurella multocida is the causative agent of fowl cholera, a disease much affecting the poultry industry. In order to study the efficacy of the recombinant subunit vaccine constructed with ptfA gene of avian P. multocida, the ptfA gene fragment amplified by PCR from avian P. multocida was cloned into the prokaryotic expression vector pET32a and the recombinant plasmid pET32a-ptfA was o...
متن کاملSafety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis
Background: Intravenous immunoglobulin (IVIG) is an established treatment of immune mediated demyelinating neuropathy including Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. IVIG exerts a number of effects, which may be beneficial in treating multiple sclerosis (MS): R...
متن کاملEffect of IL-2 co-expressed or co-inoculated with immuno-dominant epitopes from VP1 protein of FMD virus on immune responses in BALB/c mice
Objective(s): The results of studies on vaccine development for foot-and-mouth disease (FMD) virus show that the use of inactivated vaccines for FMD virus is not completely effective. Novel vaccinations based on immuno-dominant epitopes have been shown to induce immune responses. Furthermore, for safety of immunization, access to efficient adjuvants against FMD virus seems to be critical.Materi...
متن کاملImmunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis
BACKGROUND Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-gamma1b (rIFN-gammab) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. METHODOLOGY/PRINCIPAL FINDINGS We performed a randomized, controlled clinical trial of directly observed the...
متن کامل